Clinical Study

Durvalumab Vs Placebo With Stereotactic Body Radiation Therapy In Early Stage Unresected Non-Small Cell Lung Cancer Patients (Pacific-4)

Posted Date: Sep 28, 2020

  • Investigator: Emily Daugherty
  • Specialties: Cancer, Lung Cancer, Oncology, Radiation Oncology
  • Type of Study: Drug

A Phase III, Randomized, Placebo-controlled, Double-blind, Multi-center, International Study of Durvalumab With Stereotactic Body Radiation Therapy (SBRT) for the Treatment of Patients With Unresected Stage I/II, Lymph-node Negative Non-small Cell Lung Cancer (PACIFIC-4/RTOG-3515) The primary objective of this study is to assess the efficacy of durvalumab/immunotherapy with standard of care stereotactic body radiation therapy for compared to placebo with SBRT for patients with early stage lung cancer.

Criteria:

Stage I To Ii Nsclc, With Clinical Stage I/Ii Lymph Node-Negative (T1 To T3n0m0) Disease And Planned To Receive Definitive Treatment With Sbrt

Keywords:

Lung Cancer, Stereotactic Body Radiation Therapy (Sbrt), Immunotherapy

For More Information:

Emily Daugherty, Md
513-584-4073
daugheec@ucmail.uc.edu


  • This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
    For questions regarding clinical studies at UC Health, contact us at ResearchStudies@UCHealth.com or (513) 245-3417.